Center for Reproductive Medicine, Tianjin Central Hospital of Obstetrics and Gynecology, Maternal Hospital of Nankai University, Tianjin Key Laboratory of Human Development and Reproductive Regulation, Tianjin, China.
Tianjin Medical University, Tianjin, China.
PeerJ. 2024 Sep 26;12:e18112. doi: 10.7717/peerj.18112. eCollection 2024.
Coronavirus disease 2019 (COVID-19) has raised concerns about its potential effects on human fertility, particularly among individuals undergoing assisted reproductive therapy (ART). However, the impact of COVID-19 on female reproductive and assisted reproductive outcomes is unclear. In this study, we aimed to evaluate the effects of COVID-19 on pregnancy outcomes during frozen-thawed embryo transfer (FET) cycles.
This retrospective cohort study included 327 enrolled patients who underwent FET cycles at a single reproductive centre. The study group consisted of patients treated between 1 January 2023 and 31 March 2023 who recently recovered from COVID-19. The embryos for transfer were generated prior to COVID-19 infection. The control group consisted of patients treated between 1 January 2021 and 31 March 2021 who were not infected and did not receive a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Demographic and cycle characteristics and outcomes were compared.
A total of 160 recovered women and 167 controls were included. The primary outcome-the live birth rate-was similar between the two groups (43.8% 43.1%, > 0.05). The secondary outcomes, such as the implantation rates (41.2% 39.3%), biochemical pregnancy rates (56.3% 56.3%), clinical pregnancy rates (52.5% 52.1%), early abortion rates (8.3% 12.6%) and ongoing pregnancy rates (46.9% 44.3%), were also similar ( < 0.05). According to a logistic regression model, the live birth rate did not decrease after SARS-CoV-2 infection after adjusting for confounding factors (adjusted OR (95% CI) = 0.953 (0.597∼1.523)). Regardless of stratification by age or the number of embryos transferred, the differences remained nonsignificant. Subgroup logistic regression demonstrated that the time interval from infection to transplant had no significant influence on the live birth rate.
SARS-CoV-2 infection after oocyte retrieval had no detrimental effect on subsequent FET outcomes.
2019 年冠状病毒病（COVID-19）引发了人们对其可能对人类生育能力产生影响的担忧，尤其是在接受辅助生殖治疗（ART）的个体中。然而，COVID-19 对女性生殖和辅助生殖结局的影响尚不清楚。在这项研究中，我们旨在评估 COVID-19 对冷冻胚胎移植（FET）周期妊娠结局的影响。
这是一项回顾性队列研究，纳入了在一家生殖中心接受 FET 周期治疗的 327 名患者。研究组包括在 2023 年 1 月 1 日至 3 月 31 日期间最近从 COVID-19 中康复的患者。用于移植的胚胎是在 COVID-19 感染之前生成的。对照组包括在 2021 年 1 月 1 日至 3 月 31 日期间接受治疗且未感染且未接种严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗的患者。比较了两组的人口统计学和周期特征及结局。
共有 160 名康复女性和 167 名对照者纳入研究。主要结局——活产率在两组之间相似（43.8% 43.1%，>0.05）。次要结局，如种植率（41.2% 39.3%）、生化妊娠率（56.3% 56.3%）、临床妊娠率（52.5% 52.1%）、早期流产率（8.3% 12.6%）和持续妊娠率（46.9% 44.3%）也相似（<0.05）。根据逻辑回归模型，在调整混杂因素后，SARS-CoV-2 感染后活产率并未下降（调整后的比值比（95%CI）=0.953（0.597∼1.523））。无论按年龄或移植胚胎数量分层，差异均无统计学意义。亚组逻辑回归表明，从感染到移植的时间间隔对活产率没有显著影响。
取卵后感染 SARS-CoV-2 对随后的 FET 结局没有不良影响。
